A PHP Error was encountered

Severity: Warning

Message: fopen(/var/lib/php/sessions/ci_sessionqflv7h8m50q57ao1akk50cb0vdqisaph): Failed to open stream: No space left on device

Filename: drivers/Session_files_driver.php

Line Number: 177

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

A PHP Error was encountered

Severity: Warning

Message: session_start(): Failed to read session data: user (path: /var/lib/php/sessions)

Filename: Session/Session.php

Line Number: 137

Backtrace:

File: /var/www/html/index.php
Line: 316
Function: require_once

First Department of Medicine Tokyo Wome... Publications | LitMetric

5 results match your criteria: "First Department of Medicine Tokyo Women's Medical University School of Medicine Tokyo Japan.[Affiliation]"

Article Synopsis
  • Evolocumab, a monoclonal antibody approved for treating familial hypercholesterolemia (FH) and hypercholesterolemia, was evaluated in a real-world study in Japan, as data on its effectiveness and safety were previously limited.
  • The study involved 3724 patients with various forms of FH and hypercholesterolemia over 104 weeks, measuring both safety (incidences of adverse reactions) and effectiveness (changes in LDL cholesterol levels).
  • Results indicated that Evolocumab was well tolerated, showing significant reductions in LDL cholesterol levels, with low rates of serious adverse events, suggesting it is a viable treatment option for high-risk patients in Japan.
View Article and Find Full Text PDF

Evolocumab is the first monoclonal antibody against proprotein convertase subtilisin/kexin type 9 (PCSK9) approved in Japan for the treatment of patients with familial hypercholesterolemia (FH) and hypercholesterolemia (HC). This study assessed the 12-week effectiveness and safety of low-density lipoprotein cholesterol (LDL-C)-lowering therapy by PCSK9 inhibition in patients with FH (homozygous [HoFH] or heterozygous [HeFH]) and HC by analyzing evolocumab data collected in the real-world setting in Japan. Overall, 427 patients (mean±SD age, 61.

View Article and Find Full Text PDF

A 65-year-old man was diagnosed with granulomatosis with polyangiitis (GPA) at the age of 47, when cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) serology was positive, and he had multiple nodular shadows in both lungs. He had been treated with prednisolone, cyclophosphamide (CPA) and plasma exchange. At the age of 64, a nodular shadow was newly detected in the right lower lung field and serum tumour marker increased.

View Article and Find Full Text PDF

Diffuse panbronchiolitis (DPB) and asthma are obstructive airway diseases, the former being characterized by Th1-type and the latter by Th2-type airway inflammation. Differential diagnosis is often a problem, but coexistence has rarely been reported. A 76-year-old man with asthma was admitted to our hospital because of one-month history of dyspnoea on exertion with bilateral diffuse granular shadows.

View Article and Find Full Text PDF

A 25-year-old Japanese woman suffered from repeated respiratory tract infections. Because of her characteristic medical history and imaging findings, we suspected primary ciliary dyskinesia (PCD) and performed a transbronchial biopsy. The biopsy revealed complex abnormalities of the ciliary structure including cleavage of the B-subfibers observed by transmission electron microscopy analysis and the complete loss of ciliary motion by video analysis.

View Article and Find Full Text PDF